| 46.4 -1.53 (-3.19%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.75 | 1-year : | 73.29 |
| Resists | First : | 53.72 | Second : | 62.75 |
| Pivot price | 44.51  |
|||
| Supports | First : | 41.94 |
Second : | 34.66 |
| MAs | MA(5) : | 46.18 |
MA(20) : | 43.08 |
| MA(100) : | 30.47 |
MA(250) : | 21.61 |
|
| MACD | MACD : | 2.9 |
Signal : | 2.9 |
| %K %D | K(14,3) : | 56.6 |
D(3) : | 55 |
| RSI | RSI(14): 59.1 |
|||
| 52-week | High : | 53.72 | Low : | 8.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QTTB ] has closed below upper band by 35.0%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 51.1 - 51.35 | 51.35 - 51.55 |
| Low: | 45.73 - 46.05 | 46.05 - 46.31 |
| Close: | 45.96 - 46.44 | 46.44 - 46.82 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Tue, 17 Sep 2024
Q32 Bio (NASDAQ:QTTB) Trading 8.2% Higher - MarketBeat
Mon, 16 Sep 2024
Harvard Management Co. Inc. Makes New Investment in Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Wed, 11 Sep 2024
Q32 Bio's Stock (NASDAQ:QTTB) Hits 52 Week High As Wells Fargo Initiates With Lofty Price Target - AskTraders
Wed, 11 Sep 2024
Wells Fargo Initiates Coverage of Q32 Bio (QTTB) with Overweight Recommendation - MSN
Thu, 29 Aug 2024
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 (NASDAQ:QTTB) - Seeking Alpha
Mon, 12 Aug 2024
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 9.1 (%) |
| Held by Institutions | 73.7 (%) |
| Shares Short | 313 (K) |
| Shares Short P.Month | 275 (K) |
| EPS | -4.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.78 |
| Profit Margin | 0 % |
| Operating Margin | 518.3 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -1.07 |
| EBITDA (p.s.) | -5.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -10.32 |
| PEG Ratio | 0.8 |
| Price to Book value | 16.63 |
| Price to Sales | -43.72 |
| Price to Cash Flow | -17.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|